The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint.
Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute
Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeu
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS